Completed PHASE1 INTERVENTIONAL 1-arm NCT03733587

GX-I7 With Cyclophosphamide in Patients With Metastatic or Recurrent Solid Tumors

A Phase 1b Study of GX-I7 in Combination With Cyclophosphamide in Patients With Metastatic or Recurrent Solid Tumors

Sponsor: Genexine, Inc.

Updated 6 times since 2018 Last updated: May 12, 2020 Started: Oct 17, 2018 Primary completion: Apr 2, 2020 Completion: May 13, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Solid Tumor and is currently completed. Genexine, Inc. leads this study, which shows 6 recorded versions since 2018 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1
Sep 2024 — Sep 2025 [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2020 — Jan 2021 [monthly]

Completed PHASE1

Status: Recruiting → Completed · Phase: PHASE1_PHASE2 → PHASE1

▶ Show 1 earlier version

Dec 2018 — Jun 2020 [monthly]

Recruiting PHASE1_PHASE2

First recorded

Oct 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Genexine, Inc.

Data source: Genexine, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Seongnam-si, South Korea
• Seoul, South Korea